Here’s the latest CBD news:
An amendment proposed by U.S. Congressman Kurt Schrader (D-OR) that would prod the FDA into shaping CBD regulations and including CBD in the legal definition of a dietary supplement was approved this week.
Entitled the Hemp and Consumer Protection and Market Stabilization Act of 2021, H.R. 841 seeks to clarify the legal standing of hemp, as hemp producers and sellers in various states wrestle with conflicting state and federal policies.
Schrader and supporters of the amendment are hopeful that the added stability will bolster hemp production in states like Oregon, where Schrader presides.
Though Schrader’s amendment is separate from the Cannabis Administration & Opportunity Act, which was brought forward by Senators Cory Booker, Ron Wyden, and Chuck Schumer with the intent of federally decriminalizing cannabis “to end the decades of harm inflicted on communities of color by removing cannabis from the federal list of controlled substances,” both contain provisions that would allow CBD into the definition of a dietary supplement.
Though many of the high-profile CBD brands we review at least test for the “water activity” of their hemp extracts, Pressure Biosciences Inc. is taking this a few steps further by using their proprietary Ultra Shear TechnologyTM to “produce high quality, water-soluble nanoemulsions of CBD oil.”
As the name suggests, Pressure Bioscences Inc. specializes in three pressure-based platforms (Ultra Shear Technology, Pressure Cycling Technology, and the BaroFold Platform), namely to enhance the safety, stability, and absorption capabilities of therapeutic compounds.
With Ultra Shear Technology, the company will be able to significantly improve the stability and absorption capability of water-soluble CBD.
In other words, brands looking to develop CBD beverage lines can use this technology to ensure more consistent dosing, potency, and improved shelf life.
Partial results of a study by Canada-based pharmaceutical company Lexaria Bioscience Corp. that we reported on in June have just been released, and they bode well for hypertension sufferers looking for natural therapies.
Human Clinical Study HYPER-H21-1 tested the efficacy of Lexaria’s CBD-based product, called DehydraTECHTM 2.0, on blood pressure among patients with hypertension.
Lab reports for blood work are still being processed, but Lexaria CEO Chris Bunka described the initial results as very encouraging, as they allowed for a “rapid and sustained drop in blood pressure” in study participants with hypertension.
DehydraTECH was also fast-acting, demonstrably lowering blood pressure (systolic more than diastolic) throughout the patient group within less than an hour.
As the hard data is released and the study is officially published, we’ll make sure to keep you updated.